CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray Sells 2,500 Shares

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CFO Debanjan Ray sold 2,500 shares of the stock in a transaction that occurred on Wednesday, August 9th. The shares were sold at an average price of $15.00, for a total transaction of $37,500.00. Following the completion of the transaction, the chief financial officer now owns 19,626 shares in the company, valued at $294,390. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Debanjan Ray also recently made the following trade(s):

  • On Monday, July 3rd, Debanjan Ray sold 2,500 shares of CytomX Therapeutics stock. The shares were sold at an average price of $15.47, for a total transaction of $38,675.00.

Shares of CytomX Therapeutics, Inc. (CTMX) remained flat at $13.85 during trading on Friday. The company had a trading volume of 72,885 shares. CytomX Therapeutics, Inc. has a one year low of $9.85 and a one year high of $20.02. The firm’s market cap is $510.61 million. The firm has a 50 day moving average price of $14.71 and a 200 day moving average price of $14.49.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.30. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. The firm had revenue of $8.75 million during the quarter, compared to the consensus estimate of $4.95 million. On average, equities analysts forecast that CytomX Therapeutics, Inc. will post ($1.47) EPS for the current fiscal year.

WARNING: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2802250/cytomx-therapeutics-inc-nasdaqctmx-cfo-debanjan-ray-sells-2500-shares.html.

Several equities analysts have commented on the stock. BidaskClub lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 24th. Cann restated a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday. Bank of America Corporation restated a “buy” rating and set a $30.00 target price (up from $28.00) on shares of CytomX Therapeutics in a research report on Wednesday. Cowen and Company restated a “buy” rating on shares of CytomX Therapeutics in a research report on Tuesday. Finally, Jefferies Group LLC restated a “buy” rating and set a $25.00 target price on shares of CytomX Therapeutics in a research report on Tuesday, June 6th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $25.60.

Several large investors have recently modified their holdings of the stock. New York State Common Retirement Fund increased its position in shares of CytomX Therapeutics by 48.8% in the second quarter. New York State Common Retirement Fund now owns 31,100 shares of the biotechnology company’s stock worth $482,000 after buying an additional 10,199 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of CytomX Therapeutics by 39.4% in the second quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock worth $254,000 after buying an additional 4,622 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in shares of CytomX Therapeutics by 183.7% in the second quarter. TIAA CREF Investment Management LLC now owns 169,552 shares of the biotechnology company’s stock worth $2,628,000 after buying an additional 109,791 shares during the last quarter. Teachers Advisors LLC increased its position in shares of CytomX Therapeutics by 49.3% in the second quarter. Teachers Advisors LLC now owns 52,211 shares of the biotechnology company’s stock worth $809,000 after buying an additional 17,250 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in shares of CytomX Therapeutics by 113.0% in the second quarter. Alliancebernstein L.P. now owns 73,690 shares of the biotechnology company’s stock worth $1,142,000 after buying an additional 39,090 shares during the last quarter. Institutional investors and hedge funds own 52.33% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.